Dose Dependent Cytotoxicity Effect of Doxorubicin on Breast Cancer Cell Line (AMJ13) Proliferation: in Vitro Study

Eman H. Hamed; Siham A. Wadi

Dose Dependent Cytotoxicity Effect of Doxorubicin on Breast Cancer Cell Line (AMJ13) Proliferation: in Vitro Study

2023

Eman H. Hamed | Siham A. Wadi

The purpose of the current investigation was to identify the dose-dependent effect of doxorubicin on the proliferation of the AMJ13 cell line. The AMJ13 breast cancer cell line was used to investigate the cytotoxicity of the medication doxorubicin. The median inhibitory concentration (IC50) was calculated using the Methyl thiazolyltetrazolium (MTT) assay. Doxorubicin's IC50 value, which ranged from 162.2 to 308,3, was 223.6. Doxorubicin inhibited the proliferation of AMJ13 cells to a greater or lesser extent at concentrations of 1000, 500, 250, 125, 62.5, and 31.2 g/ml (58.8%, 46.4%, 32.3%, 23.8%, 11.3%, and 0.896%). respectively. The percentage of cytotoxicity (CT) After 72 hours of treatment, doxorubicin inhibited MCF7 cell growth in a dose-dependent manner, with a CT% of 90% at a dosage of 50 M. To sum up, doxorubicin displays strong cytotoxicity against the AMJ13 breast cancer cell line. It could be concluded that the effect of doxorubicin on the proliferation of theAMJ13 is dose dependent. In addition, morphological changes and apoptosis significantly enhance the inhibition of growth.

اظهر المزيد [+]